ARS Pharmaceuticals, Inc.

NASDAQ:SPRY

Biotechnology

Healthcare
$3.69 -3.51%

-$0.35 today

Market cap
$370.95M
Beta
0.83
P/E (TTM)
-4.8
EPS (TTM)
-$1.99
52W Low $6.66High $18.90

Volume 1.70M

Average 1.67M

SPRY Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

ARS Pharmaceuticals, Inc.NASDAQ: SPRY

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares grows in line with its trailing trend

Q1 FY2026 weighted avg shares of 99.3M shares rose 1.3% year over year, in line with the +1.3% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 0.7% from the prior quarter. Over 3 fiscal years it compounded at +35.1% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +1.3% toward the trailing-twelve-month pace of +1.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
99.3M+0.7% QoQ
Last fiscal yearDec 2025
98.57M+1.7% YoY
LTMMar 2026
98.76M+1.3% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+1.3%——
1 year+1.7%——
3-year CAGR+35.1%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
98.57M USD
Year-over-year change
+1.7%
4-year CAGR
+35.9%

Weighted Avg Shares vs competitors

How SPRY compares with its peers on the latest reported figures

  • SPRY's LTM Mar 2026 weighted avg shares of 98.76M shares is the lowest of the 4 companies compared; the peer median is 167.52M shares.
  • Its year-over-year change of +1.3% is the lowest of 4, against a peer median of +11.9%.
  • Over three fiscal years its annual growth of +35.1% compares with a peer median of +5.9%.
SPRY Competitors Peer median
Weighted Avg Shares for SPRY and competitors
Company Period LTM YoY 3-year CAGR
MNKDMannKind CorporationLTM Mar 2026306.42M +8.4%+5.9%
XERSXeris Biopharma Holdings, Inc.LTM Mar 2026167.52M +11.9%+5.8%
AQSTAquestive Therapeutics, Inc.LTM Mar 2026113.62M +23.3%+35.8%
SPRYARS Pharmaceuticals, Inc.LTM Mar 202698.76M +1.3%+35.1%
Peer median (excluding SPRY) 167.52M+11.9%+5.9%

Competitors are the stored peer set for SPRY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue5.51M1.32M30K89.15M84.28M
Cost of Revenue213K17.12M020.56M20.42M
Gross Profit5.29M(15.8M)30K68.59M63.86M
Gross Margin96.1%-1200.9%100.0%76.9%75.8%
Research & Development20.27M18.38M20.27M19.58M13.18M
Selling, General & Admin4.69M18.66M47.28M0230.12M
Operating Expenses24.75M19.71M67.55M71.68M243.3M
Depreciation & Amortization213K319K73K79K1.37M
EBITDA(19.92M)(34.36M)(54.29M)8.37M(167.41M)
EBITDA Margin-361.9%-2611.2%-180973.3%9.4%-198.6%
Operating Income(19.45M)(35.52M)(67.52M)(3.08M)(179.45M)
Operating Margin-353.3%-2698.8%-225066.7%-3.5%-212.9%
Interest Income800K00010.67M
Interest Expense106K0002.6M
Other Income / Expenses(789K)834K13.16M11.37M8.07M
Income Before Tax(20.24M)(34.68M)(54.37M)8.29M(171.38M)
Pre-Tax Margin-367.7%-2635.4%-181216.7%9.3%-203.3%
Income Tax Expense000288K(80K)
Net Income(20.24M)(34.68M)(54.37M)8M(171.3M)
Net Margin-367.7%-2635.4%-181216.7%9.0%-203.3%
EPS (Basic)(0.70)(0.87)(0.57)0.08(1.74)
EPS (Diluted)(0.70)(0.87)(0.57)0.08(1.74)
Weighted Avg Shares28.87M39.96M95.22M96.94M98.57M
Weighted Avg Shares (Diluted)28.87M39.96M95.22M102.39M98.57M

ARS Pharmaceuticals, Inc.

NASDAQ:SPRY

Intrinsic Alpha fair value

Locked

Current Price

$3.69

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.